Pharmaceutical Market Deal Trends (2010-2015): In-Depth Analysis of Recent Deal Activity in New Research Report

30 Nov, 2015, 10:30 ET from ReportsnReports

PUNE, India, November 30, 2015 /PRNewswire/ --

ReportsnReports.com adds a 2015 publication on pharmaceutical deal trends for 2010 - 2015 with comprehensive analysis of recent deal activity for a range of deal types, such as Mergers & Acquisitions (M&A) and strategic alliances.

Complete report titled Pharmaceutical Deal Trends (2010-2015) and In-Depth Analysis of Recent Deal Activity spread across 77 pages and examining key players, covering companies involved in M&A and strategic alliance deals is now available at http://www.reportsnreports.com/reports/444383-pharmaceutical-deal-trends-2010-2015-and-in-depth-analysis-of-recent-deal-activity.html .

This research examines preference by deal type, along with disclosed deal values from 2010 to July 2015, covering start-ups, mid-level players, and big players. Pharmaceutical companies use deal activity to enhance their research activities, regulatory approach, geographic presence, commercialization, and sales. The increasing development of biologics, especially in oncology, has given a significant boost to activity in recent years. Analysis suggests that while the number of deals in 2015 (until July) was lower than the number of deals in 2014, deal value in 2015 has already exceeded that of 2014. Looking at the entire period, although strategic deals were more numerous, M&A deals had the highest deal value. Partnerships were the most preferred type of deal activity, but saw the lowest deal value. North America led in terms of region, followed by Europe and Asia-Pacific. Key deals covered in this report include the acquisition of Allergen by Actavis, asset transactions between Novartis and GlaxoSmithKline, and the partnership between Pfizer and Merck.

This report allows its readers to gain an insight into pharmaceutical deal activity via in-depth analysis of the current pharmaceutical industry, along with a focus on the most lucrative regions and therapy areas for both M&A and strategic deals. It helps examine detailed analysis of key players, covering companies involved in M&A and strategic alliance deals, important deal activity for all deal types, and deals involving companies with the most numerous and highest-value deals. Understand how the current deals market is changing, using analysis of deals by molecule type, route of administration, and stage of development and determine the most appropriate deal activity for overcoming challenges and enhancing performance, including detailed analysis of the rationale behind key recent deals.

Order a copy of Pharmaceutical Deal Trends (2010-2015) and In-Depth Analysis of Recent Deal Activity market research report published in October 2015 at http://www.reportsnreports.com/Purchase.aspx?name=444383 .

Some of the key questions that this research helps answer include which challenges in the pharmaceutical industry are encouraging deal activity? How important is deal activity to the market? What are the trends for M&A and strategic deals, and what are the key differences between the sectors? What was the trend for regional involvement in each year? How do variations in terms of therapy area preference affect deal activity? How do announced and completed deals vary? How do deals in 2014 and 2015 compare in terms of quarterly volume and value? Which regions or therapy areas have encouraged recent deal activity? Who are the key players? How do M&A deal types differ in terms of number and value? Which regions and therapy areas have been involved in M&A deals since 2013? What are the different strategic alliance deal types? Which key regions and therapy areas have been involved in strategic alliances since 2013? Which important molecule types and routes of administration have recently been involved in strategic alliances? Who are the key players in strategic alliance deals? What was the rationale behind key strategic alliance deals?

On  a related note, another research focusing only on Q2 2015 and titled Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2015 is spread across 138 pages and provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q2 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry. Read more at http://www.reportsnreports.com/reports/430453-partnerships-licensing-investments-and-ma-deals-and-trends-in-pharmaceuticals-q2-2015.html .

Explore more reports on pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds:  http: //http://www.reportsnreports.com/feed/l-latestreports.xml


SOURCE ReportsnReports